| Literature DB >> 29344413 |
Haiping Zhao1, Ziping Han1, Guangwen Li1, Sijia Zhang1, Yumin Luo1,2,3.
Abstract
Owing to a dramatic increase in average life expectancy, most countries in the world are rapidly entering an aging society. Therefore, extending health span with pharmacological agents targeting aging-related pathological changes, are now in the spotlight of gerosciences. Panax notoginseng (Burk.) F. H. Chen, a species of the genus Panax, has been called the "Miracle Root for the Preservation of Life," and has long been used as a Chinese herb with magical medicinal value. Panax notoginseng has been extensively employed in China to treat microcirculatory disturbances, inflammation, trauma, internal and external bleeding due to injury, and as a tonic. In recent years, with the deepening of the research pharmacologically, many new functions have been discovered. This review will introduce its pharmacological function on lifespan extension, anti-vascular aging, anti-brain aging, and anti-cancer properties, aiming to lay the ground for fully elucidating the potential mechanisms of Panax notoginseng's anti-aging effect to promote its clinical application.Entities:
Keywords: Panax notoginseng; aging; cancer; neurodegenerative disease; vessel
Year: 2017 PMID: 29344413 PMCID: PMC5758348 DOI: 10.14336/AD.2017.0724
Source DB: PubMed Journal: Aging Dis ISSN: 2152-5250 Impact factor: 6.745
Anti-vascular aging function and mechanism of extracts and bioactive components of Panax notoginseng.
| Compounds | Cell/tissue | Effects | Mechanisms | Refs. |
|---|---|---|---|---|
| Extracts from P. notoginseng | HUVECs | Anti-oxidation | angiotensin II type I receptor↓ | [ |
| rats | Lipid-lowering effect | serum levels of total cholesterol triglycerides, and LDL-cholesterol↓ | [ | |
| VSMCs | Inhibit VSMCs proliferation | p16-cyclin D/CDK-RB pathways↓ | [ | |
| rats | Inhibition of adventitia remodeling | Ang II levels in adventitia↓ | [ | |
| PNS | HCAECs | Anti-inflammation | TNF-α-induced monocyte adhesion↓ | [ |
| HUVECs | Anti-inflammation | ox-LDL-induced monocyte adhesion↓ | [ | |
| zymosan A treated rats | Anti-inflammation | inflammatory factors, such as integrins, IL-18, IL-1β and MMP-2, and MMP-9↓ | [ | |
| rabbits | Anti-inflammation | mRNA levels of MCP-1, IL-6, C-reactive protein and NF-κB in the aorta wall↓ | [ | |
| ApoE knockout mice | Anti-oxidation | plaque area↓ | [ | |
| zymosan A treated rats | Anti-inflammation | phosphorylation of FAK↓ | [ | |
| rats | Lipid-lowering effect | transcriptional activation of the LXRα gene promoter↑ | [ | |
| rats | Inhibition of intimal hyperplasia | expression of PCNA↓ | [ | |
| VSMCs | Inhibit VSMCs proliferation | cell cycle-related factors and ERK signal transduction↓ | [ | |
| VSMCs | Inhibit VSMCs proliferation | p53, Bax, and caspase-3 expressions↑ | [ | |
| HUVECs | antiangiogenesis | VEGF-KDR/Flk-1and PI3K-Akt-eNOS signaling pathways | [ | |
| Ginsenoside Rg1 | VSMCs | D-galactose-induced senescence | p16INK4a/Rb and p53-p21Cip1/Waf1 signaling pathways↓ | [ |
| Notoginsenoside R1 | HUVECs | modulate the fibrinolytic capacity | [ | |
| HASMCs | TNF-a-induced PAI-1 overexpression↓ | [ | ||
| human endothelial EA. hy926 cells | Anti-inflammation | oxLDL-induced inflammatory cytokines production↓ | [ | |
| ApoE knockout mice | Anti-oxidation | serum levels of GSH and SOD↑ | [ | |
| HUVECs | promotes angiogenesis | HIF-1a-mediated VEGF expression↑ | [ |
Anti-tumor effect and mechanism of extracts and bioactive components of Panax notoginseng.
| Compounds | Cells/tissues | Effects | Mechanisms | Refs. |
|---|---|---|---|---|
| Extracts from P. notoginseng | human colorectal carcinoma SW480 cells | Anti-colorectal cancer | arrest the cells in S and G2/M phases. | [ |
| human colorectal carcinoma SW480 cells | Anti-colorectal cancer | arrested cells in the synthesis phase | [ | |
| SW480 human colorectal cancer cells | Chemotherapy sensitizer | enhanced the actions of 5-fluorouracil and irinotecan | [ | |
| hepatoma Hep3B cells, Hep3B implanted SCID mice | antiproliferation activity | reduced tumor volume and weight | [ | |
| PNS | human colon cancer LoVo cell | Anti-colorectal cancer | cell cycle arrest at S phase | [ |
| 4T1 cells | Anti-breast carcinoma | genes known to inhibit metastasis↑ | [ | |
| HeLa cells | Chemotherapy sensitizer | cisplatin cytotoxicity↑ | [ | |
| Lewis lung carcinoma cells | Anti-tumor accompanied by cardiovascular disorders | expression of CD34 and vWF in tumor↓ | [ | |
| Ginsenoside Rg1 | HeLa cells | Chemotherapy sensitizer | cisplatin cytotoxicity↑ | [ |
| Ginsenoside Rd | AGS and MCF-7 cells | inhibit cell proliferation of gastric and breast cancer | TRPM7 channel activity↓ | [ |
| HeLa cell | inhibits proliferation and induces apoptosis | Bcl-2 expression↓Bax expression↑ mitochondrial transmembrane potential↓ | [ | |
| hepatocellular carcinoma HepG2 cell | inhibit metastasis | MAPK signaling↓ | [ | |
| mammary carcinoma 4T1 cells | attenuate breast cancer metastasis | depressing miR-18a-mediated Smad2 expression regulation | [ | |
| Ginsenoside Re | AGS cells | inhibits proliferation | p21 level↑ | [ |
| Notoginsenoside R1 | HCT-116 cells | Inhibition of metastasis | integrin-1 protein↓, E-selectin, ICAM-1) ↓ | [ |
| HeLa cells | Chemotherapy sensitizer | enhanced cisplatin cytotoxicity | [ | |
| BALB/c mice | Anti-lung carcinogenesis | lung cancer stem cells↓ | [ | |
| Notoginsenoside Ft1 | SH-SY5Y cells | Anti-neuroblastoma | arrested the cell cycle at S, G2/M stages | [ |
| Polysaccharide | murine H22 hepatocarcinoma | Anti-hepatocarcinoma | activated CD4(+) T-cells↑ | [ |
| Trilinolein | non-small cell lung carcinoma A549 | inhibits proliferation | modulating PI3K/Akt pathway | [ |
Figure 1.Chemical structure and proportion of five main compounds of Panax notoginseng saponins.
Figure 2.Illustration of the cellular and molecular targets of total and individual Panax notoginseng saponins (PNS) on neural cells destroyed by Alzheimer's disease
(1) Prevention of Aβ formation and Amelioration of Aβ cytotoxicity. In the non-amyloidogenic pathway, α-secretase (α-sec) cleaves amyloid precursor protein (APP) within the Aβ domain, therefore precludes the formation of Aβ. In the amyloidogenic pathway, β-secretase (β-sec) and γ-secretase cleaves APP to produce Aβ. (2). Reduction of intracellular calcium overload. Increased calcium entered cells via the voltage-gated calcium channel currents (VGCC), resulting in calcium overload. (3) Regulation of Tau protein phosphorylation. In AD, there is a reduction in the ability of Tau to bind to tubulin and promote microtubule assembly. Hyperphosphorylated Tau contributes to the destabilization of microtubules and ultimately the formation of neurofibrillary tangle (NFT). (4) Increasing the activation of the cholinergic nervous system. Acetylcholine (ACh) is synthesized in the cytosol of cholinergic presynaptic neurons from choline and acetyl-coenzyme A (acetyl-CoA) by the enzyme choline acetyltransferase (ChAT) and is then transferred into synaptic vesicles. In the synaptic cleft, ACh is rapidly hydrolyzed by the enzyme acetylcholinesterase (AChE), releasing acetate and choline. Red arrow, promotion; green arrow, inhibition.
Figure 3.Pharmacological effects and mechanisms of Panax notoginseng saponins (PNS) against Parkinson's disease
(1) Protection of dopaminergic neurons through inhibition of oxidative stress and ER stress. (2) Acting on NMDA receptors. Notoginsenoside R1 can selectively act on the NR1/NR2B subtype of NMDA receptor to inhibit the intracellular calcium overload induced by glutamate, which protect the neurons in mice. (3) Regulation of microglia activation. PNS suppressed microglial activation through depression of accessory molecules (CD40 and CD86), decreased production of inflammatory mediators (IL-6 and TNFα), and diminished release of antibacterial products (nitric oxide).